These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36915888)

  • 21. The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder.
    Calvete J; Larrinaga G; Errarte P; Martín AM; Dotor A; Esquinas C; Nunes-Xavier CE; Pulido R; López JI; Angulo JC
    Hum Pathol; 2019 Sep; 91():61-68. PubMed ID: 31279874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of bladder cancer subtypes in neurogenic bladder tumors.
    Manach Q; Cussenot O; Rouprêt M; Gamé X; Chartier-Kastler E; Reus C; Camparo P; Compérat E; Phé V
    Can J Urol; 2018 Feb; 25(1):9161-9167. PubMed ID: 29524970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular classification of patients with NMIBC predicts the efficacy of intravesical chemotherapy with pirarubicin, pharmorubicin and gemcitabine-immunohistochemistry-based classification.
    Wang T; Niu X; Zhong B
    Jpn J Clin Oncol; 2022 May; 52(6):642-649. PubMed ID: 35348732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.
    Jung M; Kim B; Moon KC
    Histopathology; 2019 Feb; 74(3):483-493. PubMed ID: 30286252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibroblast activation protein (FAP) expression in CK5/6 expressed (Basal subtype) & CK20 expressed (Luminal subtype) urothelial bladder carcinoma: an immunohistochemical study.
    Hemida AS; Aiad HAES; Hassan NA; Al Sharaky DR
    J Immunoassay Immunochem; 2022 Nov; 43(6):618-633. PubMed ID: 35787739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.
    Breyer J; Wirtz RM; Otto W; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Eidt S; Denzinger S; Burger M; Hartmann A;
    Virchows Arch; 2017 Mar; 470(3):267-274. PubMed ID: 28074276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Feasibility and Impact of Immunohistochemistry-based Molecular Subtyping for Muscle-invasive Bladder Cancer in Patients Treated with Radiation-based Therapy.
    Hesswani C; Jackson CL; Marcq G; Hardy C; Kool R; Mansure JJ; Brimo F; Berman DM; Kassouf W
    Eur Urol Open Sci; 2023 Nov; 57():22-29. PubMed ID: 38020525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancer.
    Muilwijk T; Akand M; Van der Aa F; De Coninck V; Claessens M; Hente R; Eckstein M; Allory Y; Libbrecht L; Joniau S; Gevaert T
    J Cell Mol Med; 2021 Aug; 25(16):7890-7900. PubMed ID: 34184816
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stratification of urothelial bladder carcinoma depending on immunohistochemical expression of GATA3 and CK5/6.
    Serag Eldien MM; Abdou AG; Elghrabawy GRA; Alhanafy AM; Mahmoud SF
    J Immunoassay Immunochem; 2021 Nov; 42(6):662-678. PubMed ID: 34106817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nested Variant of Urothelial Carcinoma Is a Luminal Bladder Tumor With Distinct Coexpression of the Basal Marker Cytokeratin 5/6.
    Johnson SM; Khararjian A; Legesse TB; Khani F; Robinson BD; Epstein JI; Wobker SE
    Am J Clin Pathol; 2021 Mar; 155(4):588-596. PubMed ID: 33118597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic and prognostic implications of a three-antibody molecular subtyping algorithm for non-muscle invasive bladder cancer.
    Jackson CL; Chen L; Hardy CS; Ren KY; Visram K; Bratti VF; Johnstone J; Sjödahl G; Siemens DR; Gooding RJ; Berman DM
    J Pathol Clin Res; 2022 Mar; 8(2):143-154. PubMed ID: 34697907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Three-antibody classifier for muscle invasive urothelial carcinoma and its correlation with p53 expression.
    Olkhov-Mitsel E; Hodgson A; Liu SK; Vesprini D; Xu B; Downes MR
    J Clin Pathol; 2022 Nov; 75(11):766-771. PubMed ID: 34103388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Uroplakin II as a single marker for luminal versus basal molecular subtypes in muscle invasive urothelial carcinoma.
    Pryma C; Villamil C; Gibb EA; Oo HZ; Seiler R; Contreras-Sanz A; Douglas J; Black PC; Wang G
    Virchows Arch; 2022 Sep; 481(3):397-403. PubMed ID: 35612672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of immunohistochemistry-based molecular subtype on predicting chemotherapy response and survival in patients with T1 stage bladder cancer after bladder-preserving treatment.
    Lu J; Zhang Y; Wu C; Chu C; Liu Z; Cao Y
    Jpn J Clin Oncol; 2021 Mar; 51(3):424-433. PubMed ID: 33319245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathological Features and Survival Analysis in Molecular Subtypes of Muscle-Invasive Bladder Cancer.
    Sanguedolce F; Falagario UG; Zanelli M; Palicelli A; Zizzo M; Ascani S; Tortorella S; Mancini V; Cormio A; Carrieri G; Cormio L
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical Assays for Bladder Cancer Molecular Subtyping: Optimizing Parsimony and Performance of Lund Taxonomy Classifiers.
    Hardy CSC; Ghaedi H; Slotman A; Sjödahl G; Gooding RJ; Berman DM; Jackson CL
    J Histochem Cytochem; 2022 May; 70(5):357-375. PubMed ID: 35437049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intratumoral Switch of Molecular Phenotype and Overall Survival in Muscle Invasive Bladder Cancer.
    De Carlo C; Valeri M; Rudini N; Zucali PA; Cieri M; Elefante GM; D'antonio F; Hurle R; Giordano L; Bressan A; Lazzeri M; Perrino M; Guazzoni G; Terracciano LM; Colombo P
    Cancers (Basel); 2022 Jul; 14(13):. PubMed ID: 35805028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Basal markers and prognosis in luminal breast cancer.
    Engstrøm MJ; Valla M; Bofin AM
    Breast Cancer Res Treat; 2017 Jun; 163(2):207-217. PubMed ID: 28258354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stratification of urinary bladder carcinoma based on immunohistochemical expression of CK5, CK14 and CK20.
    Al-Sharaky DR; Abdelwahed M; Asaad N; Foda A; Abdou AG
    J Immunoassay Immunochem; 2021 May; 42(3):236-251. PubMed ID: 33213275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Profiling the Biological Characteristics and Transitions through Upper Tract Tumor Origin, Bladder Recurrence, and Muscle-Invasive Bladder Progression in Upper Tract Urothelial Carcinoma.
    Shigeta K; Matsumoto K; Tanaka N; Mikami S; Kosaka T; Yasumizu Y; Takeda T; Mizuno R; Kikuchi E; Oya M
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.